INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME AND PROCESSES FOR THEIR PREPARATION

    公开(公告)号:NZ596724A

    公开(公告)日:2013-06-28

    申请号:NZ59672408

    申请日:2008-04-30

    Applicant: ABBOTT LAB

    Abstract: Disclosed herein is a process for preparaing amine and acetylene substituted [1,2,4] triazole [1,5,-a] pyrimidine compounds of general formula (I), wherein the substituents are as defined within the specification, the process comprising: coupling an aromatic halide of formula (1) with an alkyne of formula (2) in the presence of a base, a palladium catalyst and a copper (I) salt, to provide a compound of (3), or deprotonating a compound of formula (3a) in the presence of base and treating the resulting anion with ketones or aldehydes of formula (4) in a solvent, to provide a compound of formula (3b).

    Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists

    公开(公告)号:NZ514170A

    公开(公告)日:2005-02-25

    申请号:NZ51417097

    申请日:1997-02-12

    Applicant: ABBOTT LAB

    Abstract: A process for preparing a compound of formula (I), wherein: E is a carboxy-protecting group and R1 and R2 are loweralkyl, alkoxyalkyl, alkoxycarbonylalkyl, hydroxyalkyl, haloalkyl, haloalkoxyalkyl, alkylaminocarbonylalkyl, dialkylaminocarbonylalkyl,aminocarbonyalkenyl, alkylaminocarbonylalkenyl, dialkylaminocarbonylalkenyl, aryl, arylalkyl, aryloxyalkyl, arylalkoxyalkyl, heterocyclic and (heterocyclic)alkyl Wherein cycloalkyl, aryl and heterocyclic may be optionally substituted, provided at least one of the following conditions apply: (a) R1 is selected from haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl, and (heterocyclic)alkyl, (b) R2 is selected from haloalkyl, haloalkoxyalkyl, cycloalkylalkyl, arylalkyl, aryloxyalkyl, (c) at least on of the optionally substituted aryl groups has at least on substituent selected from hydroxyalkyl and cyano or (d) at least one of the optionally substituted heterocyclic groups has at least one substituent selected from alkyloxycarbonyl, nitro and cyano; comprises a) catalytic hydrogenation of a compound of Formula (II) b)catalytic hydrogenation of the product of step a) in the presence of an acid or a mixture of acids, and c) epimerization of the product of step b) with a base. Also described is the compound (2R, 3R, 4S)-(+)-2-(4-methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(N,N-di(n-butyl-aminocarbonylmethyl)-pyrrolidine-3-carboxylic acid. This compound can be used in the manufacture of a medicament for antagonizing endothelin treating hypertension, congestive heart failure, restinosis cerebral or myocardial ischemia or atherosclerosis, treating coronary angina, cerebral vasospasm, acute and chronic renal failure, gastric ulceration, cyclosporine-induced nephrotoxicity, endotoxin-induced toxicity, asthma, LPL-related lipoprotein disorders, proliferative diseases, acute or chronic pulmonary hypertension, platelet aggregation, thrombosis, IL-2 mediated cardio toxicity nociception, colitis, vascular permeability disorders, ischemia-reperfusion injury raynaud's disease, migraine and for treating bone pain. (62) Divided out of 503365

Patent Agency Ranking